Proof-of-concept studies ongoing in lupus nephritis (LN), systemic sclerosis (SSc) and antibody mediated rejection (AMR); topline results expected for LN in fourth quarter of 2025, SSc in second half ...

One of the main factors determining therapeutic antibodies’ half-life is the interaction between the antibody’s Fc region and ...

Imaavy (Nipocalimab-aahu ), a neonatal Fc receptor (FcRn) blocker, has been approved by the FDA for treatment of generalized myasthenia gravis in adults and adolescents with anti-acetylcholine ...

Using cryo-EM, researchers elucidated the structure of key receptors integral to fast excitatory synaptic transmission in the rat cerebellum.

Chronic pain affects millions of people in the US. Targeting an oft-overlooked brain receptor could one day offer relief.

CDK 4/6 inhibitors (CDK4/6i) remain part of the standard first-line treatment for patients with hormone receptor–positive metastatic breast cancer, offering demonstrable improvements in both ...

Imaavy is the first FcRn blocker approved for anti-AChR and anti-MuSK antibody positive patients with generalized myasthenia gravis.

FcRn blockers are medicines that block the Fc receptor. In myasthenia gravis, autoantibodies – antibodies that mistakenly target the body’s own cells and proteins – especially IgG antibodies, attack ...

No-moat Takeda Pharmaceutical is Japan’s leading pharmaceutical company by revenue. While the firm historically focused on the Japan market, management has undertaken an ambitious overhaul to ...

Albumin is a ligand for FcRn, and we have engineered a human albumin variant with increased ability to engage the receptor to enhance active transport across mucosal barriers.